Susanne Caspar CEO of Swiss botanical extraction company Linnea SA analyses Europe’s latest CBD deliberations.
WE were not surprised by the European Food Safety Authority’s (EFSA) decision to halt the Novel Food application process for cannabidiol (CBD) products.
As a company with 40 years experience producing botanical extracts mainly for the pharmaceutical, food and cosmetics industries we have encountered and overcome many regulatory hurdles.
Many players in the CBD market fail to grasp its regulatory complexities; they fail to understand that the Novel Food process cannot be dealt with in a matter of months.
We have been attempting to secure Novel Food approval for one, non-cannabinoid, product for the last three years. In that time we have been asked 23 supplementary questions from a multitude of European Commission entities.
10-Year Novel Food Wait
Novel Food is not a speedy process, at least one or two substances have been gridlocked in the process for the last 10 years!
In February we saw our 5% CBD whole plant extract validated by EFSA, along with our isolate at 99% CBD. Only for them both to be then paused alongside a further 18 applications on June 7.
For our two CBD Novel Food applications we had undertaken our own long term stability studies, a toxicology study together with one customer for our 5% full extract, and for the 99% CBD isolate we also used a lot of desktop toxicology data.
When the UK said this may not be sufficient we joined the ACI consortium which has undertaken further rodent toxicology studies for the isolate and this has now been submitted to the FSA.
While this may be enough to satisfy the FSA in the UK – and we hope that is the case – we are not sure if it will satisfy the authorities in Europe.
Our findings will be passed on to the EFSA, but it appears from its recent announcement that it also requires toxicology data on the potential impacts of CBD on humans, too.
‘Existing Data Sufficient’
We believe the existing safety data on CBD is good and should be sufficient, but it seems this doesn’t match EFSA’s expectations. While there is data from many clinical trials on CBD – we did the worldwide data research – it does not seem to be enough for them.
At this stage we don’t know what they exactly expect. We will secure further guidance from EFSA’s on-line information session later this month (June 28).
But the question that will then need to be asked is how we secure this additional data, and how long will it take – weeks or years? Only after we get this information will we know.
However, we understand there is a good chance this may lead to further, high-cost toxicology studies and take maybe a longer time, so we will need to discuss how to take this forward, either as individual companies or as consortia.
As a company which spans a range of industries from pharmaceutical to food we do find EFSA’s latest proclamation very unusual for an authority responsible for food.
The request for these data is normally the responsibility of health authorities if a product is to receive a pharmaceutical marketing authorisation.
Food Or Pharma?
This dichotomy between treating CBD as either a pharmaceutical or as a food product may well lie behind Europe’s twists and turns over the status of CBD.
Remember it was only the decision of the European Court of Justice in December 2020 which saw the EC remove its previous designation of CBD as a narcotic.
France and Italy usually have a stronger tendency towards food products than, for example, a country like Germany, which prefers to see some substances submitted as novel foods under the control of the BfArM.
Here at Linnea we prepare our cannabinoid products like we have prepared all our other products for the last 40 years – as a pharmaceutical.
We are aligned with the Swiss medical regulations and we are a GMP producer.
Nevertheless we see CBD as being suitable for either of the two camps – food supplement or pharmaceutical, depending on the indication and dosage.
CBD and CBG can help with indications for real clinical problems. Our CBD extract is used in Brazil for children with epilepsy and we have complied with its pharmaceutical regulations.
Sometimes in the CBD supplements industry you get really poor quality products which bear no similarity to that which is claimed on the label.
We believe the global CBD industry will continue to grow – we are making headway in Latin America and Asia – although each jurisdiction will be different.
The direction of travel for Europe is towards higher quality products and that is why we believe CBD should be treated as a Novel Food, no matter how arduous the approval process is.
We hope this new EFSA hurdle will not take long to overcome for both the industry and businesses like ourselves – but also for the benefit of the consumer and patient.
EFSA’s Request For Human CBD Toxicology Data Is ‘Unusual’ For a Food Authority
Susanne Caspar CEO of Swiss botanical extraction company Linnea SA analyses Europe’s latest CBD deliberations.
WE were not surprised by the European Food Safety Authority’s (EFSA) decision to halt the Novel Food application process for cannabidiol (CBD) products.
As a company with 40 years experience producing botanical extracts mainly for the pharmaceutical, food and cosmetics industries we have encountered and overcome many regulatory hurdles.
Many players in the CBD market fail to grasp its regulatory complexities; they fail to understand that the Novel Food process cannot be dealt with in a matter of months.
We have been attempting to secure Novel Food approval for one, non-cannabinoid, product for the last three years. In that time we have been asked 23 supplementary questions from a multitude of European Commission entities.
10-Year Novel Food Wait
Novel Food is not a speedy process, at least one or two substances have been gridlocked in the process for the last 10 years!
In February we saw our 5% CBD whole plant extract validated by EFSA, along with our isolate at 99% CBD. Only for them both to be then paused alongside a further 18 applications on June 7.
For our two CBD Novel Food applications we had undertaken our own long term stability studies, a toxicology study together with one customer for our 5% full extract, and for the 99% CBD isolate we also used a lot of desktop toxicology data.
When the UK said this may not be sufficient we joined the ACI consortium which has undertaken further rodent toxicology studies for the isolate and this has now been submitted to the FSA.
While this may be enough to satisfy the FSA in the UK – and we hope that is the case – we are not sure if it will satisfy the authorities in Europe.
Our findings will be passed on to the EFSA, but it appears from its recent announcement that it also requires toxicology data on the potential impacts of CBD on humans, too.
‘Existing Data Sufficient’
We believe the existing safety data on CBD is good and should be sufficient, but it seems this doesn’t match EFSA’s expectations. While there is data from many clinical trials on CBD – we did the worldwide data research – it does not seem to be enough for them.
At this stage we don’t know what they exactly expect. We will secure further guidance from EFSA’s on-line information session later this month (June 28).
But the question that will then need to be asked is how we secure this additional data, and how long will it take – weeks or years? Only after we get this information will we know.
However, we understand there is a good chance this may lead to further, high-cost toxicology studies and take maybe a longer time, so we will need to discuss how to take this forward, either as individual companies or as consortia.
As a company which spans a range of industries from pharmaceutical to food we do find EFSA’s latest proclamation very unusual for an authority responsible for food.
The request for these data is normally the responsibility of health authorities if a product is to receive a pharmaceutical marketing authorisation.
Food Or Pharma?
This dichotomy between treating CBD as either a pharmaceutical or as a food product may well lie behind Europe’s twists and turns over the status of CBD.
Remember it was only the decision of the European Court of Justice in December 2020 which saw the EC remove its previous designation of CBD as a narcotic.
France and Italy usually have a stronger tendency towards food products than, for example, a country like Germany, which prefers to see some substances submitted as novel foods under the control of the BfArM.
Here at Linnea we prepare our cannabinoid products like we have prepared all our other products for the last 40 years – as a pharmaceutical.
We are aligned with the Swiss medical regulations and we are a GMP producer.
Nevertheless we see CBD as being suitable for either of the two camps – food supplement or pharmaceutical, depending on the indication and dosage.
CBD and CBG can help with indications for real clinical problems. Our CBD extract is used in Brazil for children with epilepsy and we have complied with its pharmaceutical regulations.
Sometimes in the CBD supplements industry you get really poor quality products which bear no similarity to that which is claimed on the label.
We believe the global CBD industry will continue to grow – we are making headway in Latin America and Asia – although each jurisdiction will be different.
The direction of travel for Europe is towards higher quality products and that is why we believe CBD should be treated as a Novel Food, no matter how arduous the approval process is.
We hope this new EFSA hurdle will not take long to overcome for both the industry and businesses like ourselves – but also for the benefit of the consumer and patient.
Democrats rushing to pass cannabis reform before midterms
Next PostCantourage UK Brings Together Pharma’s Uganda-Grown Medical Cannabis To The United Kingdom
Peter
Related Posts
Related Posts
Hawaii Lawmakers Shoot Down Second Cannabis Reform Bill This Month
Hawaii lawmakers have shot down another attempt at cannabis reform, just weeks after a landmark legalization bill was killed in...
It Is High Time for a Renaissance in the UK Cannabis Industry
Written for Business of Cannabis by Andrew Pepper, Partner at business restructuring and consultancy firm ReSolve Advisory. In January...
Pressure Piles on DEA to Make a Decision on Cannabis Rescheduling as 21 Senators Demand Action
Chill Brands CEO Suspended Amid Allegations Of ‘Use of Inside Information’, SynBiotic Buys Croatian CBD Maker, & Hellenic Secures Funding
Tikun Olam Europe Leads the Change in Greece’s Rapidly Evolving Medical Cannabis Landscape
Cannabis Associations in Germany Face New Restrictions in Push to Prevent Commercialisation
CONNECT
Related Posts
Related Posts
Hawaii Lawmakers Shoot Down Second Cannabis Reform Bill This Month
Hawaii lawmakers have shot down another attempt at cannabis reform, just weeks after a landmark legalization bill was killed in...
It Is High Time for a Renaissance in the UK Cannabis Industry
Written for Business of Cannabis by Andrew Pepper, Partner at business restructuring and consultancy firm ReSolve Advisory. In January...
Pressure Piles on DEA to Make a Decision on Cannabis Rescheduling as 21 Senators Demand Action
Pressure is mounting on the US Drug Enforcement Agency (DEA) to come forward with its decision on cannabis rescheduling as...
Chill Brands CEO Suspended Amid Allegations Of ‘Use of Inside Information’, SynBiotic Buys Croatian CBD Maker, & Hellenic Secures Funding
Chill Brands Chill Brands has seen its share price dive by nearly 40% this week after news emerged that...
Tikun Olam Europe Leads the Change in Greece’s Rapidly Evolving Medical Cannabis Landscape
Earlier this year, Greece became the latest EU country to make medical cannabis products available to patients. In February 2024,...
Recent Posts
Related Posts
Jersey Hemp Wins Watershed Legal Battle Against UK Home Office Which Threatened Entire CBD Industry
Jersey Hemp has won a watershed court battle against the UK Home Office, which has now admitted acting unlawfully in...
The Future of CBD in Japan: How Legal Reforms Will Shape the Market
Late last year, Japan made a major step towards cannabis reform after approving a bill to amend its 75-year-old Cannabis...
Chill Brands Stock Drops on News of Vaping Ban, Voyager Life Aquires CBD Retailer, & Pharma C Rebrands
Chill Brands Chill Brands has seen its stock price drop by more than 30% this week following news that...
Hemp Industry Calls on House Energy & Commerce Leaders to Hold Crucial Hearing on FDA Regulation
In a significant move to address the challenges faced by the U.S. hemp industry, 28 non-profit organizations – representing every...
Hemp Industry Calls on House Energy & Commerce Leaders to Hold Crucial Hearing on FDA Regulation
In a significant move to address the challenges faced by the U.S. hemp industry, 28 non-profit organizations – representing every...
Subscribe to our mailing list to receives daily updates!
We won’t spam you
Categories
Browse by Tags